Newain (CEO Kim Dohyung) and Neuroventi (CEO Shin Chanyoung), tenant companies at Seoul Bio Hub, announced that they have signed a business agreement to develop electronic medicine for the treatment of neurodevelopmental disorders such as Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD).
Newain and Neuroventi possess technological expertise in different fields?electronic medicine and neurodevelopmental disorder treatment research, respectively?and have formed a strategic alliance by combining their unique technologies and infrastructure to develop treatments for ADHD and ASD through brain nerve stimulation, embarking on a new challenge.
This treatment protocol based on electronic medicine technology is already actively used in clinical settings in the United States following FDA approval.
A representative from Newain stated, “Currently, drug therapy is the most effective treatment for ADHD or ASD, but since there can be side effects or addiction issues from receiving drug treatment from a young age, we hope to quickly apply this technology domestically to address these concerns.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
